Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therap... (+44 (0)20 7404 5959 Justine McIlroy ....)

Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

Date:12/13/2007

+44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.

SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package. This three-in-one device allows ... in their designs - cutting installation time by ...

(Date:6/18/2013)... GARDEN CITY, N.Y. , June 18, 2013 ... announced that it has entered into an exclusive ... and Mid-Atlantic regions with eWellness Corporation ("EWC") for ... "An easy to use physical therapy program ... of diabetes and cardiovascular disease," said Chris ...

(Date:6/18/2013)... a letter to authorities at her hospital, orthopaedic surgeon ... Iowa , writes that a policy of forcing all ... justified nor ethically sound. Her letter is the ... the Journal of American Physicians and Surgeons. ... of 36,000 patients per year die in U.S. hospitals from ...

Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3 Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2

[0] Three-in-One X3130 Appliance Inlet Module [0] Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions [0] Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes

... Ga., Dec. 23, 2010 MiMedx Group, ... integrated developer, manufacturer and marketer of patent protected biomaterial-based ... the Class III certification for a European product using ... certification for "post surgical adhesion inhibiting barriers" is in ...

... Pa., Dec. 23, 2010 Cephalon, Inc. (Nasdaq: ... appointed J. Kevin Buchi as Chief Executive Officer and a ... role of company Chairman in the future. William P. Egan ... "Kevin is an experienced pharmaceutical executive who has been ...

Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 2 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 3 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 4

MiMedx Receives Additional CE Certification for Its HydroFix™ Technology Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors

(Date:6/19/2013)... Pharmaceutical history is replete with ... with little or no understanding why they work, ... involved emerging years later. When Edward Tobinick ... rapid recovery of cognitive functions after perispinally administering ... known about the role inflammatory processes play in ...

(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Middle ... throughout 2013 across all industries as cash rich buyers ... the differences across industries, all M&A transactions have a ... due diligence to verify the history and quality of ... considered. , But when due diligence involves a ...

(Date:6/19/2013)... Over the past five years, revenue ... has been growing at an annualized rate of 9.5% ... have supported the development of the industry including: substantial ... relatively higher drug prices in hospitals; and people's increased ... the development of chain drug retailing enterprises has also ...

(Date:6/18/2013)... Angeles, CA (PRWEB) June 19, 2013 ... of bariatric surgery, are holding complimentary weight loss seminars ... the detailed program can be accessed at their official ... minimizes surgery and recovery time. Their highly skilled panel ... to bariatric surgery. , A senior executive working ...

(Date:6/18/2013)... 18, 2013 Exposed Skin Care has finally ... acne suffers of all ages finally achieve the clear, beautiful ... products, this new acne clearing system combines the power of ... new acne from forming. , After a quick ... products are some of the most effective available on the ...

Breaking Medicine News(10 mins):Health News:Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2 Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3 Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3

[0] Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's [0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld [0] oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June [0] Exposed Skin Care Review Released by ExposedSkinCareReview.org

... AUSTIN, Texas Employees who have more control over their ... to be in better health, according to a new study ... month,s Journal of Health and Social Behavior. , "The most ... said lead author John Mirowsky, a sociology professor with the ...

... 18, 2007 -- Phylonix Pharmaceuticals today announced that it ... 135 531 B1: Methods for Introducing Heterologous Cells into ... European countries, encompasses 68 claims, including transplanting stem cells, ... chondrocytes, renal and hepatic cells can be transplanted in ...

... CBS News will be running the,story December 17th and ... CHEMOTHERAPY, THANKS TO A NEW ROBOT THAT MEASURES AND ... PharmD, PhD, and,a patient were interviewed by CBS News. ... compounding for syringes and IV bags.,University of Colorado Hospital ...

... AIDS Healthcare,Foundation (AHF) today strongly criticized Ryan White ... package drafted by Congress in order,to meet the ... for,next year. The fiscal year 2008 Labor-Health and ... today and is,expected to be introduced in the ...

... Toronto Stock Exchange Symbol: CYT, MONTREAL, Dec. 17 ... products to treat cardiovascular,disease, today announced financial results for ... Selected FY 2007 Financial and Operating Highlights:, ... portfolio to ATS Medical, we ...

... ... -, TOPEKA, Kan., Dec. ... Kansas, which will,help support the needs of more than 7,700 Kansas Guard members ... at,TriWest, will present the check to the Adjutant General of the Kansas,National Guard, ...

Creative work has health advantages, Population Research Center study shows Phylonix granted broad European patent for transplanting human cells into zebrafish CytoCare Showcased on CBS News Nationally and CBS Affiliates Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF CryoCath announces 2007 fourth quarter and fiscal year end financial results TriWest Contributes $15,000 to Kansas National Guard Fund

Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...

Medicine Products:

7F High Flow 6F Infiniti 5F Infiniti Infinity